ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces First Patient Enrolled in Phase II Randomized Controlled Study of IMM0306 for the Treatment of Systemic Lupus Erythematosus

ImmuneOnco Secures IND Approval for amulirafusp alfa (IMM0306) in Primary Sjögren's Syndrome

A National Investigators' Meeting for the "Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study of IMM0306 for Injection (Amulirafusp Alfa) in Combination with Lenalidomide versus Placebo in Combination with Lenalidomide in Subjects with Relapsed/Refractory Follicular Lymphoma," sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco"), was successfully held in Harbin.

This milestone marks a critical step in the formulation optimization of the IMM2510 program, promising a superior treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.

This milestone represents a solid step forward in the clinical development of IMC-003, laying a crucial foundation for evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics under multiple dosing regimens, and holding promise to bring new hope to patients suffering from PAH.